Attovia Therapeutics is a clinical-stage biopharmaceutical company developing biologic therapies for immune-mediated diseases. The company utilizes its ATTOBODY platform, licensed from Alamar Biosciences, to create biparatopic antibodies that bind two distinct epitopes on a single target molecule. This modular architecture allows Attovia to develop monospecific, bispecific, and trispecific formats with high potency. The company’s lead candidate, ATTO-1310, is a monospecific IL-31 blocker for chronic itch conditions that has completed Phase 1 dosing, with Phase 2 trials planned for H1 2027. Attovia is also advancing ATTO-2306, a bispecific targeting IL-13 and IL-31 for atopic dermatitis, and ATTO-1091, a trispecific targeting TL1A, IL-23, and α4β7 for inflammatory bowel disease. Both programs are in IND-enabling studies with Phase 1 trials expected to begin in H1 2027. Attovia's business model focuses on advancing these candidates through clinical development toward regulatory approval or strategic partnerships. The company maintains a lean fixed-cost base by outsourcing manufacturing and clinical execution to third-party contract organizations. Beyond its lead assets, Attovia’s strategy includes developing earlier-stage multispecific programs for respiratory and rheumatological diseases and pursuing selective licensing agreements to generate non-dilutive capital.